Minneapolis Heart Institute   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Minneapolis MN United States (1982)

Organization Overview

First Clinical Trial
2005
NCT00268307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Minneapolis Heart Institute | Minneapolis Heart Institute and Foundation/ Abbott Northwestern Hospital-Allina Health | Minneapolis Heart Institute Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 4)

Atrial Fibrillation (Phase 4)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cardiovascular Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Heart Failure (Phase 2)

Infarction (Phase 1)

Ischemia (Phase 1)

Myocardial Infarction (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 12